ClinicalTrials.gg
Active, not recruitingNCT06910566TABAC STOP ORLUpdated Mar 18, 2026

Factors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy

An observational study in Smoking Cessation, Nicotine Addiction and Nicotine Dependence, sponsored by Centre Oscar Lambret. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Centre Oscar Lambret · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Smoking Cessation with a site in France — 8 open to participants now, 11 under way, 1 of them phase 3. Smoking Cessation · France.

Started
2022
with 5 others
Observational
5 of 48
1 open now
Primary completion
2026-11
later than 4 of 10 live
Registered
44th of 48
by date

Among the 48 studies in Smoking Cessation with a site in France, this one is one of 6 that started in 2022, is one of 5 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 44th registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

8 of the 48 studies in Smoking Cessation with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Smoking Cessation with a site in France, or all of them as a file.
02

Study summary

The TABAC STOP ORL POUMON study aims to evaluate the factors influencing long-term smoking cessation in patients with head and neck cancer (HNC) or lung cancer undergoing radiotherapy or chemoradiotherapy. This is a single-center observational study, following patients at 1, 6, and 12 months after treatment completion. The primary objective is to determine the proportion of abstinent patients at 6 months, while secondary objectives analyze factors influencing abstinence, smoking trajectories, and reasons for relapse. A total of 100 patients will be included to ensure robust statistical analysis.

Read the detailed description

The TABAC STOP ORL POUMON study is a prospective, single-center observational study aiming to understand factors influencing long-term smoking cessation in patients treated for head and neck or lung cancer. Tobacco is a leading cause of death and disease, particularly in areas like Hauts-de-France with high smoking rates.

Eligible patients, undergoing radiotherapy or chemoradiotherapy, are enrolled during the final week of treatment, completing questionnaires assessing nicotine dependence and alcohol use. Follow-ups are scheduled at 1, 6, and 12 months, through clinic visits or phone interviews.

The primary endpoint is the proportion of patients who remain smoke-free at 6 months. Secondary endpoints include factors influencing smoking cessation, reasons for relapse, and changes in nicotine and alcohol dependence. The study will enroll 100 patients, expecting 81 evaluable cases, with data quality ensured through regular checks and source verification.

03

Conditions studied

  • Smoking Cessation
  • Nicotine Addiction
  • Nicotine Dependence
  • Smoking
  • Head and Neck Neoplasms

Keywords

  • Tobacco abstinence
  • Head and neck cancer
  • Smoking cessation
  • Nicotine dependence
  • Cancer treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of patients diagnosed with head and neck cancer (HNC) or lung cancer, who are undergoing curative treatment with chemoradiotherapy, radiotherapy alone, or stereotactic radiotherapy at the Centre Oscar Lambret in Lille, France. Participants are current or former smokers and are recruited during the last week of their radiotherapy treatment. The study aims to evaluate factors associated with maintaining tobacco abstinence in this specific patient population, focusing on their smoking cessation journey following cancer treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 18 years or older
  • Diagnosed with head and neck cancer or lung cancer
  • Undergoing curative treatment with chemoradiotherapy, radiotherapy alone, or stereotactic radiotherapy
  • Current or former smoker
  • Patient covered by a social security scheme
  • Patient informed and having given consent for data collection

Patients with human papillomavirus (HPV) may also be included

Exclusion criteria

Exclusion Criteria :

  • Patient receiving palliative treatment
  • Patient under guardianship or curatorship

Study Exit Criteria :

- Protocol-defined exit : After the 12-month consultation

Early exit :

  • Withdrawal of consent for data collection
  • Death of the patient
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • ProcedureChemoradiotherapy or radiotherapy alone

    Patients included in the study receive standard treatment with chemoradiotherapy or radiotherapy alone for their head and neck cancer or lung cancer. These treatments are part of their routine care and are not part of the observational study.

    Also known as: chemoradiotherapy, radiotherapy

06

What researchers measure

Primary outcomes

  1. Abstinence at 1 month and 6 months after the end of treatment

    The primary outcome measure will be abstinence at 1 month (physical consultation or telephone follow-up) and at 6 months after the end of treatment.

    Time frame: 1 and 6 months after the end of treatment.

Secondary outcomes

  1. Proportion of patients willing to attend a smoking cessation consultation

    Evaluation of patients willing to attend a smoking cessation consultation (assessed among active smokers at the phone follow-up consultation).

    Time frame: At the 1-month telephone follow-up after the end of treatment.

  2. Abstinence at 1 month after the end of treatment

    Proportion of tobacco-abstinent patients 1 month after the end of radiotherapy or chemoradiotherapy

    Time frame: 1 month after the end of treatment

  3. Abstinence at 6 months after the end of treatment

    Proportion of tobacco-abstinent patients 6 months after the end of radiotherapy or chemoradiotherapy

    Time frame: 6 months after the end of treatment

  4. Abstinence at 12 months after the end of treatment

    Proportion of tobacco-abstinent patients 12 months after the end of radiotherapy or chemoradiotherapy

    Time frame: 12 months after the end of treatment

  5. Cigarette dependence (Cigarette Dependence Scale, CDS)

    Level of nicotine dependence assessed using the Cigarette Dependence Scale (CDS). The CDS is a validated 12-item scale with scores ranging from 0 to 60, where higher scores indicate dependence.

    Time frame: Baseline

  6. Alcohol use and dependence (Alcohol Use Disorders Identification Test, AUDIT)

    Alcohol consumption and dependence assessed using the Alcohol Use Disorders Identification Test (AUDIT). The AUDIT is a 10-item scale with scores ranging from 0 to 40, where higher scores indicate higher risk of alcohol-related harm.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Nov 2026, 56 months after the start.

Of 42 non-industry observational studies under Smoking Cessation, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 56 months is above that.

Counting every sponsor, half of 47 studies reached it within 28 months; a quarter within 14 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Apr 4, 2025
StartActual
Mar 28, 2022
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06910566
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Mar 28, 2022
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Mar 18, 2026

Study contacts

Gautier LEFEBVRE, MD
study director · Centre Oscar Lambret

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion